日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Partial regression of conventional renal cell carcinoma displays markers of wound repair.

传统肾细胞癌的部分消退显示出伤口修复的标志

Domonkos Lilla, Yusenko Maria, Kovacs Gyula, Banyai Daniel

Optical Genome Mapping Reveals Disruption of the RASGRF2 Gene in a Patient with Developmental Delay Carrying a De Novo Balanced Reciprocal Translocation

光学基因组图谱分析揭示,一名发育迟缓患者携带新生平衡易位,其RASGRF2基因发生破坏。

Lederbogen, Rosa Catalina; Hoffjan, Sabine; Thiels, Charlotte; Mau-Holzmann, Ulrike Angelika; Singer, Sylke; Yusenko, Maria Viktorovna; Nguyen, Hoa Huu Phuc; Gerding, Wanda Maria

Multimodal 4-arylchromene derivatives with microtubule-destabilizing, anti-angiogenic, and MYB-inhibitory activities

具有微管解聚、抗血管生成和MYB抑制活性的多模式4-芳基色烯衍生物

Köhler, Leonhard H F; Reich, Sebastian; Yusenko, Maria; Klempnauer, Karl-Heinz; Begemann, Gerrit; Schobert, Rainer; Biersack, Bernhard

C/EBPβ is a MYB- and p300-cooperating pro-leukemogenic factor and promising drug target in acute myeloid leukemia

C/EBPβ 是一种与 MYB 和 p300 协同作用的促白血病因子,也是急性髓系白血病中一个很有前景的药物靶点。

Yusenko, Maria V; Trentmann, Amke; Casolari, Debora A; Abdel Ghani, Luca; Lenz, Mairin; Horn, Melanie; Dörner, Wolfgang; Klempnauer, Stefan; Mootz, Henning D; Arteaga, Maria Francisca; Mikesch, Jan-Henrik; D'Andrea, Richard J; Gonda, Thomas J; Müller-Tidow, Carsten; Schmidt, Thomas J; Klempnauer, Karl-Heinz

Expression of TXNIP is associated with angiogenesis and postoperative relapse of conventional renal cell carcinoma

TXNIP的表达与血管生成和常规肾细胞癌的术后复发相关

Meszaros, Mate; Yusenko, Maria; Domonkos, Lilla; Peterfi, Lehel; Kovacs, Gyula; Banyai, Daniel

Dual role of KRT17: development of papillary renal cell tumor and progression of conventional renal cell carcinoma

KRT17的双重作用:乳头状肾细胞肿瘤的发生和常规肾细胞癌的进展

Sarlos, Donat Peter; Yusenko, Maria V; Peterfi, Lehel; Szanto, Arpad; Kovacs, Gyula

A novel cell-based screening assay for small-molecule MYB inhibitors identifies podophyllotoxins teniposide and etoposide as inhibitors of MYB activity

一种新型的基于细胞的小分子MYB抑制剂筛选方法,鉴定出鬼臼毒素类化合物替尼泊苷和依托泊苷是MYB活性抑制剂。

Yusenko, Maria; Jakobs, Anke; Klempnauer, Karl-Heinz